SM
ISEE

SG3 Management’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

SG3 Management’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-40,000
Closed -$656K – 1362
2021
Q3 		$650K Buy
+40,000
New +$435K 0.02% 548

Other funds holding ISEE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

SG3 Management's ISEE Position: Q4 2021 in Review

SG3 Management sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q4 2021, closing a stake of 40,000 shares — an estimated $656K sold.

SG3 Management first reported a position in ISEE in Q3 2021 and held it in 1 quarter. The position peaked at $650K in Q3 2021. 175 funds tracked by Wall St. Rank hold ISEE as of Q4 2021.

  • SG3 Management reported no remaining IVERIC bio, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • SG3 Management sold 40,000 IVERIC bio, Inc. Common Stock shares in Q4 2021, an estimated $656K.
  • SG3 Management first reported a position in IVERIC bio, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • SG3 Management's IVERIC bio, Inc. Common Stock position peaked at $650K in Q3 2021.
  • 175 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.